Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Al B Benson

Showing results (121-130 of 350) with videos related to

Pageof 35
Sort By:
International Journal of Radiation Oncology, Biology, Physics|March 15, 2016
Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial DesignLawrence R Kleinberg, Paul J Catalano, Arlene A Forastiere, et al.
Journal of the National Cancer Institute|August 8, 2002
Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancerA David McCollum, Paul J Catalano, Daniel G Haller, et al.
International Journal of Radiation Oncology, Biology, Physics|August 30, 2008
Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297David I Rosenthal, Paul J Catalano, Daniel G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Impact of diabetes mellitus on outcomes in patients with colon cancerJeffrey A Meyerhardt, Paul J Catalano, Daniel G Haller, et al.
Cancer|July 25, 2003
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinomaJeffrey A Meyerhardt, Paul J Catalano, Daniel G Haller, et al.
The Oncologist|August 7, 2014
Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review studyJonathan R Strosberg, Al B Benson, Lynn Huynh, et al.
Annals of Surgery|October 22, 2015
Adjusted Hospital Sentinel Lymph Node Positivity Rates in Melanoma: A Novel Potential Measure of QualityChristine V Kinnier, Jennifer L Paruch, Allison R Dahlke, et al.
Journal of Translational Medicine|February 11, 2020
MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinomaAydin Eresen, Jia Yang, Junjie Shangguan, et al.
Cancer Treatment Reviews|April 24, 2012
Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumorsJohn M Kirkwood, Ahmad Tarhini, Joseph A Sparano, et al.
Cancer Research Communications|September 18, 2025
A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid TumorsChristopher H Lieu, Heinz-Josef Lenz, Al B Benson, et al.
Pageof 35

Showing results (121-130 of 350) with videos related to

Sort By:
Pageof 35
International Journal of Radiation Oncology, Biology, Physics|March 15, 2016
Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial DesignLawrence R Kleinberg, Paul J Catalano, Arlene A Forastiere, et al.
Journal of the National Cancer Institute|August 8, 2002
Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancerA David McCollum, Paul J Catalano, Daniel G Haller, et al.
International Journal of Radiation Oncology, Biology, Physics|August 30, 2008
Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297David I Rosenthal, Paul J Catalano, Daniel G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Impact of diabetes mellitus on outcomes in patients with colon cancerJeffrey A Meyerhardt, Paul J Catalano, Daniel G Haller, et al.
Cancer|July 25, 2003
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinomaJeffrey A Meyerhardt, Paul J Catalano, Daniel G Haller, et al.
The Oncologist|August 7, 2014
Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review studyJonathan R Strosberg, Al B Benson, Lynn Huynh, et al.
Annals of Surgery|October 22, 2015
Adjusted Hospital Sentinel Lymph Node Positivity Rates in Melanoma: A Novel Potential Measure of QualityChristine V Kinnier, Jennifer L Paruch, Allison R Dahlke, et al.
Journal of Translational Medicine|February 11, 2020
MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinomaAydin Eresen, Jia Yang, Junjie Shangguan, et al.
Cancer Treatment Reviews|April 24, 2012
Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumorsJohn M Kirkwood, Ahmad Tarhini, Joseph A Sparano, et al.
Cancer Research Communications|September 18, 2025
A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid TumorsChristopher H Lieu, Heinz-Josef Lenz, Al B Benson, et al.
Pageof 35